Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 2(4)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05607004Phase 2Recruiting

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Role: lead

NCT05068388Phase 2Active Not Recruiting

Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

Role: lead

NCT02540330Phase 2Terminated

A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

Role: lead

NCT02121873Completed

The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage

Role: lead

NCT04616430Phase 2Completed

Topical Endoxifen in Women

Role: lead

NCT04519788Phase 1Completed

AT-301 Nasal Spray in Healthy Adults

Role: lead

NCT02218385Completed

ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid

Role: lead

NCT02539615Phase 3Withdrawn

A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old

Role: lead

All 8 trials loaded